147 related articles for article (PubMed ID: 25434444)
1. [Therapeutic effect of rebamipide for oral mucositis associated with FEC therapy for breast cancer].
Enami A; Masuda N; Yamamura J; Mizutani M; Yasojima H; Shikata A; Masaoka M; Takada S; Bamba N; Yamamoto M; Abe M; Makihara K
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1407-12. PubMed ID: 25434444
[TBL] [Abstract][Full Text] [Related]
2. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I
J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study.
Yokota T; Ogawa T; Takahashi S; Okami K; Fujii T; Tanaka K; Iwae S; Ota I; Ueda T; Monden N; Matsuura K; Kojima H; Ueda S; Sasaki K; Fujimoto Y; Hasegawa Y; Beppu T; Nishimori H; Hirano S; Naka Y; Matsushima Y; Fujii M; Tahara M
BMC Cancer; 2017 May; 17(1):314. PubMed ID: 28476132
[TBL] [Abstract][Full Text] [Related]
4. [Pilot study on clinical effects of rebamipide gargle against oral mucositis induced by fluoropyrimidines].
Kabeya M; Ina K; Yuasa S; Kikuchi F; Tajiri C; Kato T; Hibi S; Minagawa Y; Furuta R; Kayukawa S; Kataoka T; Kawai M
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1133-6. PubMed ID: 21772097
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Fumoleau P; Kerbrat P; Romestaing P; Fargeot P; Brémond A; Namer M; Schraub S; Goudier MJ; Mihura J; Monnier A; Clavère P; Serin D; Seffert P; Pourny C; Facchini T; Jacquin JP; Sztermer JF; Datchary J; Ramos R; Luporsi E
J Clin Oncol; 2003 Jan; 21(2):298-305. PubMed ID: 12525522
[TBL] [Abstract][Full Text] [Related]
6. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Del Mastro L; De Placido S; Bruzzi P; De Laurentiis M; Boni C; Cavazzini G; Durando A; Turletti A; Nisticò C; Valle E; Garrone O; Puglisi F; Montemurro F; Barni S; Ardizzoni A; Gamucci T; Colantuoni G; Giuliano M; Gravina A; Papaldo P; Bighin C; Bisagni G; Forestieri V; Cognetti F;
Lancet; 2015 May; 385(9980):1863-72. PubMed ID: 25740286
[TBL] [Abstract][Full Text] [Related]
7. [High incidence-rate of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy (FEC100)].
Fukazawa M; Kawaguchi H; Shigematsu H; Koga C; Mori E; Nishimura S; Nakamura Y; Satou S; Sawamura K; Kashiwaba K; Ohno S
Gan To Kagaku Ryoho; 2012 Mar; 39(3):395-8. PubMed ID: 22421766
[TBL] [Abstract][Full Text] [Related]
8. Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma.
Capotorto AM; Pavesi L; Pedrazzoli P; Da Prada GA; Zamagni C; Massidda B; Farris A; Martoni A; Lelli G; Robustelli della Cuna G
J Chemother; 2003 Apr; 15(2):184-91. PubMed ID: 12797397
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory breast cancer outcome with epirubicin-based induction and maintenance chemotherapy: ten-year results from the French Adjuvant Study Group GETIS 02 Trial.
Veyret C; Levy C; Chollet P; Merrouche Y; Roche H; Kerbrat P; Fumoleau P; Fargeot P; Clavere P; Chevallier B
Cancer; 2006 Dec; 107(11):2535-44. PubMed ID: 17054108
[TBL] [Abstract][Full Text] [Related]
10. FEC (5-fluorouracil-epirubicin-cyclophosphamide) monthly versus FEC weekly in metastatic breast cancer. First results of a randomized trial.
Blomqvist C; Elomaa I; Rissanen P; Hietanen P; Nevasaari K; Helle L
Acta Oncol; 1992; 31(2):231-6. PubMed ID: 1622639
[TBL] [Abstract][Full Text] [Related]
11. Acute hematologic feasibility of G-CSF supported dose-escalated FEC therapy as adjuvant treatment after breast cancer surgery.
Ottosson S; Magnusson K; Hultborn R
Anticancer Res; 1999; 19(5C):4429-34. PubMed ID: 10650787
[TBL] [Abstract][Full Text] [Related]
12. [The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Kim SJ; Taguchi T; Miyoshi Y; Tanji Y; Tamaki Y; Noguchi S
Gan To Kagaku Ryoho; 2005 Nov; 32(12):1919-23. PubMed ID: 16282727
[TBL] [Abstract][Full Text] [Related]
13. Rebamipide gargle and benzydamine gargle in prevention and management of chemo-radiotherapy and radiotherapy-induced oral mucositis in head and neck cancer patients (randomized clinical trial).
Elsaadany B; Anayb SM; Mashhour K; Yossif M; Zahran F
BMC Oral Health; 2024 Jun; 24(1):645. PubMed ID: 38824583
[TBL] [Abstract][Full Text] [Related]
14. [A pilot study of rebamipide-gargle for chemoradiotherapy-induced mucositis in oral cancer patients].
Yasuda T; Chiba H; Satomi T; Matsuo A; Kaneko T; Miyamatsu H
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1157-61. PubMed ID: 18633254
[TBL] [Abstract][Full Text] [Related]
15. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
[TBL] [Abstract][Full Text] [Related]
16. Rebamipide attenuates 5-Fluorouracil-induced small intestinal mucositis in a mouse model.
Kim HJ; Kim JH; Moon W; Park J; Park SJ; Song GA; Han SH; Lee JH
Biol Pharm Bull; 2015; 38(2):179-83. PubMed ID: 25747976
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy of Rebamipide Gargle against Chemotherapy-induced Oral Mucositis].
Shinohara A; Nakamura M; Onikubo T; Nakamura K
Yakugaku Zasshi; 2015; 135(8):937-41. PubMed ID: 26234350
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of rebamipide-loaded PLGA nanoparticles coated with chitosan in a mouse model for oral mucositis induced by cancer chemotherapy.
Takeuchi I; Kamiki Y; Makino K
Colloids Surf B Biointerfaces; 2018 Jul; 167():468-473. PubMed ID: 29723818
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness of antimycotic agents (itraconazole) in chemotherapy-induced mucositis of breast cancer patients].
Tsuyuki S; Kawaguchi K; Kawata Y; Yamaguchi A; Kanazawa A; Sugitatsu M; Kono Y
Gan To Kagaku Ryoho; 2012 Sep; 39(9):1369-73. PubMed ID: 22996771
[TBL] [Abstract][Full Text] [Related]
20. Epirubicin versus mitoxantrone in combination chemotherapy for metastatic breast cancer.
Pavesi L; Preti P; Da Prada G; Pedrazzoli P; Poggi G; Robustelli della Cuna G
Anticancer Res; 1995; 15(2):495-501. PubMed ID: 7763029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
